Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
Stocks in this Quantisnow insightHealth Care
Historical context for KYTX
Across the 22 sessions after earlier KYTX headlines, the stock closed higher 7 times and lower 14 times, with a median move of 5.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KYTX | SPY |
|---|---|---|---|
| May 18, 2026 | Kyverna Therapeutics Names Greg Martini as Chief Financial Officer | -10.0% | -0.1% |
| May 14, 2026 | Kyverna Therapeutics to Present at Upcoming Investor Conferences | -0.4% | +0.8% |
| May 13, 2026 | Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results | +5.4% | +0.6% |
| May 4, 2026 | Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer | +1.5% | -0.4% |
| Apr 22, 2026 | Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting | +5.4% | +1.0% |
| Apr 20, 2026 | Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks | +13.3% | -0.2% |
Quantisnow market dataNASDAQ
KYTX
Kyverna Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2024
Get push alerts for KYTX
Full KYTX profile on Quantisnow Follow KYTX and get a push notification the moment its next story breaks.